Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 20 of 253

1.

Comparison of GenesWell BCT Score With Oncotype DX Recurrence Score for Risk Classification in Asian Women With Hormone Receptor-Positive, HER2-Negative Early Breast Cancer.

Kwon MJ, Lee JE, Jeong J, Woo SU, Han J, Kang BI, Kim JE, Moon Y, Lee SB, Lee S, Choi YL, Kwon Y, Song K, Gong G, Shin YK.

Front Oncol. 2019 Jul 24;9:667. doi: 10.3389/fonc.2019.00667. eCollection 2019.

2.

Chemoresistance in the Human Triple-Negative Breast Cancer Cell Line MDA-MB-231 Induced by Doxorubicin Gradient Is Associated with Epigenetic Alterations in Histone Deacetylase.

Han J, Lim W, You D, Jeong Y, Kim S, Lee JE, Shin TH, Lee G, Park S.

J Oncol. 2019 Jun 2;2019:1345026. doi: 10.1155/2019/1345026. eCollection 2019.

3.

Clinical Features and Outcomes of Invasive Breast Cancer: Age-Specific Analysis of a Modern Hospital-Based Registry.

Kim JY, Kang D, Nam SJ, Kim SW, Lee JE, Yu JH, Lee SK, Im YH, Ahn JS, Guallar E, Cho J, Park YH.

J Glob Oncol. 2019 Jul;5:1-9. doi: 10.1200/JGO.19.00034.

4.
5.

Insights Into Breast Cancer in the East vs the West: A Review.

Yap YS, Lu YS, Tamura K, Lee JE, Ko EY, Park YH, Cao AY, Lin CH, Toi M, Wu J, Lee SC.

JAMA Oncol. 2019 May 16. doi: 10.1001/jamaoncol.2019.0620. [Epub ahead of print]

PMID:
31095268
6.

Prediction of axillary pathologic response with breast pathologic complete response after neoadjuvant chemotherapy.

Choi HJ, Ryu JM, Kim I, Nam SJ, Kim SW, Yu J, Lee JE, Lee SK.

Breast Cancer Res Treat. 2019 Aug;176(3):591-596. doi: 10.1007/s10549-019-05214-y. Epub 2019 May 7.

PMID:
31065874
7.

Nomogram for accurate prediction of breast and axillary pathologic response after neoadjuvant chemotherapy in node positive patients with breast cancer.

Choi HJ, Ryu JM, Kim I, Nam SJ, Kim SW, Yu J, Lee JE, Lee SK.

Ann Surg Treat Res. 2019 Apr;96(4):169-176. doi: 10.4174/astr.2019.96.4.169. Epub 2019 Mar 28.

8.

Practical approaches to automated digital image analysis of Ki-67 labeling index in 997 breast carcinomas and causes of discordance with visual assessment.

Kwon AY, Park HY, Hyeon J, Nam SJ, Kim SW, Lee JE, Yu JH, Lee SK, Cho SY, Cho EY.

PLoS One. 2019 Feb 20;14(2):e0212309. doi: 10.1371/journal.pone.0212309. eCollection 2019.

9.

Retrospectively validating the results of the ACOSOG Z0011 trial in a large Asian Z0011-eligible cohort.

Jung J, Han W, Lee ES, Jung SY, Han JH, Noh DY, Kim Y, Choi HJ, Lee JE, Nam SJ, Lee JW, Kim HJ, Um E, Kim JH, Park S, Cho YU.

Breast Cancer Res Treat. 2019 May;175(1):203-215. doi: 10.1007/s10549-019-05157-4. Epub 2019 Feb 4.

PMID:
30715659
10.

The association between non-breast and ovary cancers and BRCA mutation in first- and second-degree relatives of high-risk breast cancer patients: a large-scale study of Koreans.

Kim H, Choi DH, Park W, Im YH, Ahn JS, Park YH, Nam SJ, Kim SW, Lee JE, Yu JH, Lee SK, Jung BY.

Hered Cancer Clin Pract. 2019 Jan 3;17:1. doi: 10.1186/s13053-018-0103-3. eCollection 2019.

11.

Patterns of Axillary Lymph Node Metastasis in Breast Cancer: A Prospective Single-Center Study.

Choi HJ, Kim JM, Ryu JM, Kim I, Nam SJ, Yu J, Lee SK, Lee JE, Kim SW.

J Breast Cancer. 2018 Dec;21(4):447-452. doi: 10.4048/jbc.2018.21.e50. Epub 2018 Oct 29.

12.

Use of Sentinel Lymph Node Biopsy after Neoadjuvant Chemotherapy in Patients with Axillary Node-Positive Breast Cancer in Diagnosis.

Choi HJ, Kim I, Alsharif E, Park S, Kim JM, Ryu JM, Nam SJ, Kim SW, Yu J, Lee SK, Lee JE.

J Breast Cancer. 2018 Dec;21(4):433-441. doi: 10.4048/jbc.2018.21.e54. Epub 2018 Nov 23.

13.

Serum Trace Elements and Their Associations with Breast Cancer Subgroups in Korean Breast Cancer Patients.

Choi R, Kim MJ, Sohn I, Kim S, Kim I, Ryu JM, Choi HJ, Kim JM, Lee SK, Yu J, Kim SW, Nam SJ, Lee JE, Lee SY.

Nutrients. 2018 Dec 24;11(1). pii: E37. doi: 10.3390/nu11010037.

14.

TP53 upregulates α‑smooth muscle actin expression in tamoxifen‑resistant breast cancer cells.

Kim S, You D, Jeong Y, Yu J, Kim SW, Nam SJ, Lee JE.

Oncol Rep. 2019 Feb;41(2):1075-1082. doi: 10.3892/or.2018.6910. Epub 2018 Dec 6.

PMID:
30535478
15.

Prognostic value of immunohistochemically detected p53 in adjuvant chemotherapy-treated triple negative breast cancer.

Bae SY, Jung SP, Lee SK, Yu J, Lee JE, Kim SW, Nam SJ.

Kaohsiung J Med Sci. 2018 Dec;34(12):663-672. doi: 10.1016/j.kjms.2018.07.003. Epub 2018 Aug 23.

16.

Berberine down-regulates IL-8 expression through inhibition of the EGFR/MEK/ERK pathway in triple-negative breast cancer cells.

Kim S, You D, Jeong Y, Yu J, Kim SW, Nam SJ, Lee JE.

Phytomedicine. 2018 Nov 15;50:43-49. doi: 10.1016/j.phymed.2018.08.004. Epub 2018 Aug 7.

PMID:
30466991
17.

BCT score predicts chemotherapy benefit in Asian patients with hormone receptor-positive, HER2-negative, lymph node-negative breast cancer.

Kwon MJ, Lee SB, Han J, Lee JE, Lee JW, Gong G, Beitsch PD, Nam SJ, Ahn SH, Nam BH, Shin YK.

PLoS One. 2018 Nov 21;13(11):e0207155. doi: 10.1371/journal.pone.0207155. eCollection 2018.

18.

Reclassification of BRCA1 and BRCA2 variants of uncertain significance: a multifactorial analysis of multicentre prospective cohort.

Lee JS, Oh S, Park SK, Lee MH, Lee JW, Kim SW, Son BH, Noh DY, Lee JE, Park HL, Kim MJ, Cho SI, Lee YK, Park SS, Seong MW.

J Med Genet. 2018 Dec;55(12):794-802. doi: 10.1136/jmedgenet-2018-105565. Epub 2018 Nov 10.

PMID:
30415210
19.

Formation of size-controllable tumour spheroids using a microfluidic pillar array (μFPA) device.

Lim W, Hoang HH, You D, Han J, Lee JE, Kim S, Park S.

Analyst. 2018 Nov 19;143(23):5841-5848. doi: 10.1039/c8an01752b.

PMID:
30379148
20.

Prevalence and oncologic outcomes of BRCA 1/2 mutations in unselected triple-negative breast cancer patients in Korea.

Ryu JM, Choi HJ, Kim I, Nam SJ, Kim SW, Yu J, Lee SK, Choi DH, Park YH, Kim JW, Seo JS, Park JH, Lee JE, Kim SW; Korean Hereditary Breast Cancer Study Group.

Breast Cancer Res Treat. 2019 Jan;173(2):385-395. doi: 10.1007/s10549-018-5015-4. Epub 2018 Oct 22.

PMID:
30350268

Supplemental Content

Loading ...
Support Center